Danaher Corporation

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $5.47B normalized FCF base (TTM/FY2025 free cash flow, consistent with OCF $6.64B less capex); 7% annual FCF growth years 1-5 (matching current sell-side consensus revenue growth of 7.2%-8.1%); 5% years 6-10 (fade toward GDP+ growth); 8.5% discount rate; 3% terminal growth; $23.51B net debt (total debt $27.86B, cash $4.35B); 702.99M diluted shares.

Reasoning: Danaher is a stable, high-margin, cash-generative life-sciences and diagnostics-tools compounder with reliable FCF conversion, making a standard multi-stage unlevered DCF appropriate, with near-term growth anchored to actual analyst consensus rather than assumption.